Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Abstract: Genes involved in the inflammation pathway have been associated with cancer risk. Genetic variants in the interleukin-6 (IL6) and prostaglandin-endoperoxide synthase-2 (PTGS2, encoding for the COX-2 enzyme) genes, in particular, have been related to several cancer types, including breast and prostate cancers. We conducted a study within the Breast and Prostate Cancer Cohort Consortium to examine the association between IL6 and PTGS2 polymorphisms and breast and prostate cancer risk. Twenty-seven polymorphisms, selected by pairwise tagging, were genotyped on 6292 breast cancer cases and 8135 matched controls and 8008 prostate cancer cases and 8604 matched controls. The large sample sizes and comprehensive single nucleotide polymorphism tagging in this study gave us excellent power to detect modest effects for common variants. After adjustment for multiple testing, none of the associations examined remained statistically significant at P = 0.01. In analyses not adjusted for multiple testing, one IL6 polymorphism (rs6949149) was marginally associated with breast cancer risk (TT versus GG, odds ratios (OR): 1.32; 99% confidence intervals (CI): 1.00-1.74, P(trend) = 0.003) and two were marginally associated with prostate cancer risk (rs6969502-AA versus rs6969502-GG, OR: 0.87, 99% CI: 0.75-1.02; P(trend) = 0.002 and rs7805828-AA versus rs7805828-GG, OR: 1.11, 99% CI: 0.99-1.26; P(trend) = 0.007). An increase in breast cancer risk was observed for the PTGS2 polymorphism rs7550380 (TT versus GG, OR: 1.38, 99% CI: 1.04-1.83). No association was observed between PTGS2 polymorphisms and prostate cancer risk. In conclusion, common genetic variation in these two genes might play at best a limited role in breast and prostate cancers.
    Type of Publication: Journal article published
    PubMed ID: 19965896
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; GROWTH ; proliferation ; PATHWAY ; PROSTATE ; COHORT ; DISEASE ; HISTORY ; RISK ; GENE ; GENES ; FAMILY ; CARCINOGENESIS ; ASSOCIATION ; polymorphism ; POLYMORPHISMS ; single nucleotide polymorphism ; VARIANTS ; BREAST ; STAGE ; AGE ; OVARIAN-CANCER ; SNP ; MEN ; PROSTATE-CANCER ; FACTOR-I ; CELL-MIGRATION ; PHOSPHOINOSITIDE 3-KINASE ; signaling ; ONCOLOGY ; REGRESSION ; ASSOCIATIONS ; VARIANT ; SINGLE NUCLEOTIDE POLYMORPHISMS ; GROWTH-FACTOR-I ; BINDING PROTEIN-3 ; SINGLE-NUCLEOTIDE POLYMORPHISMS ; PHOSPHATIDYLINOSITOL 3-KINASE ; FACTOR (IGF)-I ; pooled analysis ; FAMILY-HISTORY ; INCREASED RISK ; CANCER-RISK ; genetic association ; single nucleotide ; REGULATORY SUBUNIT
    Abstract: The phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, including cellular proliferation and intracellular trafficking, and may affect prostate carcinogenesis. Thus, we explored the association between single-nucleotide polymorphisms (SNP) in PI3K genes and prostate cancer. Pooled data from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium were examined for associations between 89 SNPs in PI3K genes (PIK3C2B, PIK3AP1, PIK3C2A, PIK3CD, and PIK3R3) and prostate cancer risk in 8,309 cases and 9,286 controls. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. SNP rs7556371 in PIK3C2B was significantly associated with prostate cancer risk [ORper (allele), 1.08 (95% CI, 1.03-1.14); P-trend = 0.0017] after adjustment for multiple testing (P-adj = 0.024). Simultaneous adjustment of rs7556371 for nearby SNPs strengthened the association [ORper (allele), 1.21 (95% CI, 1.09-1.34); P-trend = 0.0003]. The adjusted association was stronger for men who were diagnosed before the age of 65 years [ORper (allele), 1.47 (95% CI, 1.20-1.79); P-trend = 0.0001] or had a family history [ORper (allele) = 1.57 (95% CI, 1.11-2.23); P-trend = 0.0114], and was strongest in those with both characteristics [ORper (allele) = 2.31 (95% CI, 1.07-5.07), P-interaction = 0.005]. Increased risks were observed among men in the top tertile of circulating insulin-like growth factor-I (IGF-I) levels [ORper (allele) = 1.46 (95% CI, 1.04-2.06); P-trend = 0.075]. No differences were observed with disease aggressiveness (Gleason grade = 8 or stage T-3/T-4 or fatal). In conclusion, we observed a significant association between PIK3C2B and prostate cancer risk, especially for familial, early-onset disease, which may be attributable to IGF-dependent PI3K signaling. Cancer Res; 70(6); 2389-96. (C)2010 AACR
    Type of Publication: Journal article published
    PubMed ID: 20197460
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...